ES2041641T3 - Granulos que contienen vitaminas y procedimientos para su produccion. - Google Patents

Granulos que contienen vitaminas y procedimientos para su produccion.

Info

Publication number
ES2041641T3
ES2041641T3 ES198686307598T ES86307598T ES2041641T3 ES 2041641 T3 ES2041641 T3 ES 2041641T3 ES 198686307598 T ES198686307598 T ES 198686307598T ES 86307598 T ES86307598 T ES 86307598T ES 2041641 T3 ES2041641 T3 ES 2041641T3
Authority
ES
Spain
Prior art keywords
sub
granules
vitamin
compounds
powders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686307598T
Other languages
English (en)
Inventor
Seiji Izuhara
Nobuyuki Kitamori
Masaya Maeno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16808227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2041641(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2041641T3 publication Critical patent/ES2041641T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyridine Compounds (AREA)

Abstract

PUEDE PREPARARSE UN GRANULO QUE CONTIENE VITAMINA Y QUE COMPRENDE SUSTANCIALMENTE UNO O MAS COMPUESTOS SELECCIONADOS DEL GRUPO QUE CONSISTE EN VITAMINAS B6 Y B2, NICOTINAMIDA Y UNA SAL DEL ACIDO PANTOTENICO Y UN AGENTE AGLOMERANTE, CONSTITUYENDO DICHO COMPUESTO U COMPUESTOS DEL 90 AL 99% EN PESO EN SECO, APLICANDO A LOS POLVOS DE DICHO COMPUESTO O COMPUESTOS UN RECUBRIMIENTO POR PULVERIZACION DE UNA SOLUCION QUE CONTIENE UN AGLOMERANTE, MIENTRAS SE MANTIENEN LOS POLVOS EN ESTADO FLUIDIFICADO EN UN APARATO DE GRANULACION EN LECHO FLUIDIFICADOS. SUS GRANULOS SON MUY FLUIDOS Y SE MEZCLAN BIEN CON OTROS MEDICAMENTOS, GRANULOS, ADITIVOS, ETC. ADEMAS, LOS GRANULOS SE COMPRIMEN MUY BIEN, POR LO QUE PUEDEN TRANSFORMARSE EN TABLETAS CON POCO EXCIPIENTE Y ESTAS SON DE UNA DUREZA SATISFACTORIAMENTE ALTA.
ES198686307598T 1985-10-07 1986-10-02 Granulos que contienen vitaminas y procedimientos para su produccion. Expired - Lifetime ES2041641T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22407985 1985-10-07

Publications (1)

Publication Number Publication Date
ES2041641T3 true ES2041641T3 (es) 1993-12-01

Family

ID=16808227

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198686307598T Expired - Lifetime ES2041641T3 (es) 1985-10-07 1986-10-02 Granulos que contienen vitaminas y procedimientos para su produccion.

Country Status (11)

Country Link
US (1) US4868180A (es)
EP (1) EP0219276B1 (es)
JP (1) JPH0751504B2 (es)
KR (1) KR930008951B1 (es)
CN (1) CN1022024C (es)
AT (1) ATE77942T1 (es)
AU (1) AU587863B2 (es)
CA (1) CA1308024C (es)
DE (1) DE3685927T2 (es)
DK (1) DK167339B1 (es)
ES (1) ES2041641T3 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2689458B2 (ja) * 1988-02-09 1997-12-10 武田薬品工業株式会社 粒状ないし粉末状のビタミンb▲下1▼▲下2▼類含有組成物
LU87145A1 (fr) * 1988-02-26 1989-09-20 Oreal Methode pour ameliorer l'aspect esthetique de la peau a l'aide de melanges polyvitaminiques
ATE99545T1 (de) * 1989-03-29 1994-01-15 Takeda Chemical Industries Ltd Zusammensetzung mit einer verbindung der vitamin b-gruppe und ihre herstellung.
JP2591235B2 (ja) * 1989-03-30 1997-03-19 吉富製薬株式会社 アルキルシステインまたはその酸付加塩を含有する安定な錠剤
US5034389A (en) * 1989-07-28 1991-07-23 Coors Biotech, Inc. Riboflavin composition and method for production
DE3927810A1 (de) * 1989-08-23 1991-02-28 Basf Ag Riboflavingranulate
GB8922701D0 (en) * 1989-10-09 1989-11-22 Leung Lit Hung Compositions and methods for weight reduction
US5254551A (en) * 1990-04-30 1993-10-19 Kirk Paula S Flour fortification formulation comprising granulated riboflavin
US4994458A (en) * 1990-04-30 1991-02-19 Basf Corporation Process for rotary fluid bed granulation of riboflavin
US5236920A (en) * 1990-04-30 1993-08-17 Basf Corporation Granulated riboflavin product having high flowability, high riboflavin content
DE4014262A1 (de) * 1990-05-04 1991-11-07 Basf Ag Gut rieselfaehige, nichtstaubende bindemittelfreie riboflavinspruehgranulate oder -mikrogranulate aus reinem riboflavin und ein verfahren zu deren herstellung
US5000888A (en) * 1990-05-23 1991-03-19 Basf Corporation Process for spray drying riboflavin to produce a granulate product having low binder content
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
GB2252905B (en) * 1991-02-11 1995-05-10 Leung Lit Hung An agent for correcting a deficiency of androgenic steroids
GB2252729B (en) * 1991-02-13 1994-11-09 Bharat Sridhar Pancham Vitamin and/or mineral containing pharmaceutical compositions
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993013756A1 (en) * 1992-01-10 1993-07-22 Obschestvo S Ogranichennoy Otvetstvennostyu Meditsinsky Nauchno-Proizvodstvennoy Komplex 'biotiki' Granulated pharmaceutical composition and method of obtaining it
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
US5635535A (en) * 1996-04-05 1997-06-03 Wagstaff; Robert K. Method for increasing blood glucose levels
JP4098376B2 (ja) * 1996-09-05 2008-06-11 ビーエーエスエフ ソシエタス・ヨーロピア 錠剤特性の優れた水溶性ビタミン組成物およびその製造法
US6093715A (en) * 1999-03-24 2000-07-25 Basf Aktiengesellschaft Process for producing riboflavin-containing granules
JP2001031567A (ja) * 1999-05-20 2001-02-06 Takeda Chem Ind Ltd アスコルビン酸塩含有組成物
DE10032349A1 (de) 2000-07-04 2002-01-17 Degussa Rieselfähige D-Pantothensäure und/oder deren Salze enthaltende Futtermittel-Additive und Verfahren zu deren Herstellung
IT1320776B1 (it) * 2000-08-07 2003-12-10 Giampiero Valletta Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie
US6773733B2 (en) 2001-03-26 2004-08-10 Loders Croklaan Usa Llc Structured particulate systems
JP2005501833A (ja) * 2001-07-30 2005-01-20 ディーエスエム アイピー アセッツ ビー.ブイ. エピガロカテキンガレートのための組成物
JP4519444B2 (ja) * 2003-10-31 2010-08-04 ライオン株式会社 口腔内崩壊錠
CA2589200A1 (en) * 2004-11-26 2006-06-01 Medicure International Inc. Formulations of pyridoxal -5'-phosphate and methods of preparation
FR2879403B1 (fr) * 2004-12-20 2007-05-11 Alept Sarl Soc Complement alimentaire destine a prevenir l'apparition des symptomes associes a la maladie d'alzheimer
JP5198001B2 (ja) * 2006-06-23 2013-05-15 武田薬品工業株式会社 安定化された固形製剤
EP2042164A4 (en) * 2006-06-23 2010-10-13 Takeda Pharmaceutical STABILIZED SOLID PREPARATION
CA2899225A1 (en) 2007-07-06 2009-01-15 Basf Se Method for the production of an aqueous glucose solution
DE102007045038A1 (de) * 2007-09-13 2009-03-19 MEDICE Arzneimittel Pütter GmbH & Co. KG Arzneimittel zur Behandlung oder Prävention von Proteinurie
CN101632648A (zh) * 2008-07-23 2010-01-27 Ss制药株式会社 薄膜包衣制剂
MX351356B (es) * 2008-11-13 2017-10-04 Com S Car Borr S A De C V Kit de formulaciones farmaceuticas caracterizado por la presencia de oxigeno molecular.
JP5584534B2 (ja) * 2009-06-30 2014-09-03 興和株式会社 安定化方法
JP5897916B2 (ja) * 2012-01-31 2016-04-06 アサヒフードアンドヘルスケア株式会社 ビタミン含有錠剤及びその製造方法
TW201402153A (zh) * 2012-04-04 2014-01-16 Lonza Ag 菸鹼醯胺粉末和其製備方法及裝置
US9510617B2 (en) 2012-04-13 2016-12-06 Frito-Lay North America, Inc. Micropellets of fine particle nutrients and methods of incorporating same into snack food products
US9271523B2 (en) 2012-05-23 2016-03-01 Dennis Williams Rotor assembly with one-piece finger member
CN103720660A (zh) * 2013-11-19 2014-04-16 华中药业股份有限公司 一种核黄素颗粒及其制备方法
JP6056064B2 (ja) * 2013-11-29 2017-01-11 国立大学法人 東京大学 卵殻膜成分を含むインスリン抵抗性改善剤ならびにそれを用いた組成物
CN105581982A (zh) * 2014-10-23 2016-05-18 华中药业股份有限公司 一种烟酰胺颗粒剂及其制备方法
CN111012748B (zh) * 2018-10-10 2022-06-10 常州市第四制药厂有限公司 维生素b12制剂及其制备方法
WO2020093192A1 (zh) * 2018-11-05 2020-05-14 重庆小丸科贸有限公司 一种水溶性活性物颗粒及其制备方法和应用
CN109771383A (zh) * 2018-12-20 2019-05-21 华中药业股份有限公司 复合维生素b颗粒、复合维生素b片及其制备方法
US20220280462A1 (en) * 2019-08-26 2022-09-08 Dsm Ip Assets B.V. Solid oral dosage form comprising naproxen and vitamin b1
CN111012755A (zh) * 2020-01-09 2020-04-17 仁和堂药业有限公司 维生素b6片的制备工艺
CN111110643A (zh) * 2020-01-09 2020-05-08 仁和堂药业有限公司 一种维生素b6片剂及其质量检测方法
CN111419808A (zh) * 2020-04-23 2020-07-17 河南海汇药物研究有限公司 一种维生素b6全粉末压片工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA678143A (en) * 1964-01-14 Hochberg Melvin Tablets for pharmaceutical use
US3308217A (en) * 1965-02-09 1967-03-07 Lowy Lawrence Method of granulating materials for subsequent forming into tablets
US3493659A (en) * 1967-10-23 1970-02-03 Hoffmann La Roche Compositions and process for the production thereof
BE791458A (fr) * 1972-07-31 1973-05-16 Merck & Co Inc Produit microencapsule
ZA739543B (en) * 1973-02-16 1975-03-26 Hoffmann La Roche Free-flowing, directly tablettable, pharmaceutically active substances
JPS58403B2 (ja) * 1975-07-24 1983-01-06 武田薬品工業株式会社 L− アスコルビンサンセイザイノ セイゾウホウ
JPS5759803A (en) * 1980-09-30 1982-04-10 Takeda Chem Ind Ltd Granule of l-sodium ascorbate, its preparation, and tablet comprising it
EP0125252A1 (de) * 1982-11-16 1984-11-21 MOTSCHAN, Georges Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine
US4486435A (en) * 1983-05-16 1984-12-04 Basf Wyandotte Corporation Spray-dried vitamin powders using hydrophobic silica
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
JPH0753663B2 (ja) * 1984-10-09 1995-06-07 武田薬品工業株式会社 チアミン塩の顆粒,その製造法および錠剤

Also Published As

Publication number Publication date
JPH0751504B2 (ja) 1995-06-05
ATE77942T1 (de) 1992-07-15
DK167339B1 (da) 1993-10-18
KR930008951B1 (ko) 1993-09-17
EP0219276A3 (en) 1988-09-21
CN1022024C (zh) 1993-09-08
JPS62174013A (ja) 1987-07-30
DE3685927T2 (de) 1992-12-24
KR870003776A (ko) 1987-05-04
CN86106839A (zh) 1988-04-20
US4868180A (en) 1989-09-19
DK459486A (da) 1987-04-08
AU6291986A (en) 1987-04-09
AU587863B2 (en) 1989-08-31
CA1308024C (en) 1992-09-29
EP0219276A2 (en) 1987-04-22
DE3685927D1 (de) 1992-08-13
DK459486D0 (da) 1986-09-26
EP0219276B1 (en) 1992-07-08

Similar Documents

Publication Publication Date Title
ES2041641T3 (es) Granulos que contienen vitaminas y procedimientos para su produccion.
DK163208C (da) Retard-praeparat af acemetacin og fremgangsmaade til fremstilling deraf
JPS55153715A (en) Prolonged granule of theophylline
JPS5215812A (en) Process for preparing an l-ascorbic acid pharmaceutical
DK616186D0 (da) Farmaceutisk praeparat med retarderet frigivelse af ibuprofen
ZA200306614B (en) Method to obtain microparticles containing a H +, K + -ATP-ase inhibitor.
MY100900A (en) Substituted phenylsulfonyloxybenzimidazolecarbamates, processes for their preparation and their use as medicaments.
US3950546A (en) Pulverulent vitamin and mineral-fortified clay product for farrowing house floor
JPS5489036A (en) Remedy and preventive for hypersensitivity to light
ZA926536B (en) Substituted mandelic acid derivatives, processes for their preparation and their use in medicaments.
CA2403110A1 (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
ATE30231T1 (de) 3-beta-(3'-(carboxypropionyloxy))-ursa-9(11),12 dien-28-carbonsaeure sowie ihre salze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
Ershoff Protective effects of cholestyramine in rats fed a low-fiber diet containing toxic doses of sodium cyclamate or amaranth
AU553742B2 (en) Antibiotic feed agent for coccidiosis
GB1478020A (en) Composition for the treatment of asthma
JPS5325534A (en) Mandelic acid glucosides and their anti-cancerous preparations
JPS539315A (en) Preparation of hardly soluble pharmaceuticals
JPS57209222A (en) Cardiac
JPS55133313A (en) Cholesterol-lowering agent
JPS57109722A (en) Antitumor agent containing deoxyfluorouridine benzyloxylated at 4-position
ES8302670A1 (es) Procedimiento de preparacion de nuevos derivados 2-hidroxi- metil-quinoxalino-1,4-dioxidos
JPS5791914A (en) Peptic unti-ulcer
Wahlstrom et al. High-Protein Oats in Ground and Pelleted Pig Starter Diets
RU2002116760A (ru) Способ производства гранулированных кормов для рыб
JPS54105237A (en) Analgesic agent containing nalorphine-6-glucuronide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 219276

Country of ref document: ES